Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
Primary Objective
1. To evaluate the safety profile of Bevacizumab (Bevacizumab™)- Rituximab (Rituxan®)-CHOP
(RA-CHOP) in patients with newly diagnosed mantle cell lymphoma (MCL).
Secondary Objectives
1. To evaluate the response rate and time to disease progression of the RA-CHOP regimen in
patients with newly diagnosed MCL.
2. To prospectively characterize the angiogenic profiles of MCL patients during RA-CHOP
treatment.